This activity was originally broadcast live at the 2022 Asembia Specialty Pharmacy Summit.
This activity features a Patient Perspective.
Program Description
Treatment options for patients with chronic lymphocytic leukemia (CLL) currently consist of an armamentarium of agents including oral targeted therapy with BTK and BCL-2 inhibitors. Overall selection of therapy can be complex as it depends on clinical staging and presence of genetic mutations, among other factors. Additionally, agents for the treatment of CLL have been associated with clinically significant adverse effects and treatment discontinuation among patients. To optimize care for patients, specialty and oncology pharmacists have important roles in providing proactive assessment and counseling for adherence and management of adverse effects associated with these oral therapies. This program will delve into elements central to treatment selection for patients with CLL as well as strategies pharmacists can utilize in the management of adverse effects associated with BTK and BCL-2 inhibitors. A Patient Perspective interview will be incorporated throughout this activity and will highlight the experience of a patient with CLL from diagnosis through treatment.
Target audience: Specialty pharmacists and oncology pharmacists
Type of activity: Application
Release date: May 10, 2022
Expiration date: May 10, 2023
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the different prognostic markers in chronic lymphocytic leukemia (CLL) and their influence on therapy selection
- Explore appropriate treatment strategies for CLL based on patient-specific factors and safety and efficacy data
- Construct a plan for use within specialty pharmacies to monitor and manage adverse effects of oral therapies for patients with CLL
- Identify important counseling points to impart to patients on oral oncolytics for the treatment of CLL
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
